6.755 USD
-0.17 (-2.53%)
Overall MDXG gets a fundamental rating of 6 out of 10. We evaluated MDXG against 531 industry peers in the Biotechnology industry. MDXG is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. A decent growth rate in combination with a cheap valuation! Better keep an eye on MDXG. These ratings would make MDXG suitable for value investing!
1. Profitability
1.1 Basic Checks
In the past year MDXG was profitable.
MDXG had a positive operating cash flow in the past year.
In multiple years MDXG reported negative net income over the last 5 years.
In multiple years MDXG reported negative operating cash flow during the last 5 years.
1.2 Ratios
With an excellent Return On Assets value of 12.80%, MDXG belongs to the best of the industry, outperforming 94.35% of the companies in the same industry.
MDXG has a better Return On Equity (17.09%) than 95.10% of its industry peers.
Looking at the Return On Invested Capital, with a value of 15.15%, MDXG belongs to the top of the industry, outperforming 95.86% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 12.8% | ||
| ROE | 17.09% | ||
| ROIC | 15.15% |
ROA(3y)4.7%
ROA(5y)-7.18%
ROE(3y)1.74%
ROE(5y)-20.73%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin of MDXG (10.38%) is better than 91.34% of its industry peers.
With an excellent Operating Margin value of 13.73%, MDXG belongs to the best of the industry, outperforming 92.84% of the companies in the same industry.
MDXG's Operating Margin has been stable in the last couple of years.
MDXG has a better Gross Margin (81.99%) than 85.50% of its industry peers.
In the last couple of years the Gross Margin of MDXG has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 13.73% | ||
| PM (TTM) | 10.38% | ||
| GM | 81.99% |
OM growth 3YN/A
OM growth 5Y-1.06%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.19%
GM growth 5Y-0.67%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so MDXG is still creating some value.
Compared to 1 year ago, MDXG has more shares outstanding
The number of shares outstanding for MDXG has been increased compared to 5 years ago.
The debt/assets ratio for MDXG has been reduced compared to a year ago.
2.2 Solvency
MDXG has an Altman-Z score of 9.97. This indicates that MDXG is financially healthy and has little risk of bankruptcy at the moment.
MDXG has a Altman-Z score of 9.97. This is amongst the best in the industry. MDXG outperforms 81.73% of its industry peers.
MDXG has a debt to FCF ratio of 0.27. This is a very positive value and a sign of high solvency as it would only need 0.27 years to pay back of all of its debts.
The Debt to FCF ratio of MDXG (0.27) is better than 95.29% of its industry peers.
A Debt/Equity ratio of 0.07 indicates that MDXG is not too dependend on debt financing.
The Debt to Equity ratio of MDXG (0.07) is worse than 62.52% of its industry peers.
Although MDXG does not score too well on debt/equity it has very limited outstanding debt, which is well covered by the FCF. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.07 | ||
| Debt/FCF | 0.27 | ||
| Altman-Z | 9.97 |
ROIC/WACC1.74
WACC8.69%
2.3 Liquidity
MDXG has a Current Ratio of 4.41. This indicates that MDXG is financially healthy and has no problem in meeting its short term obligations.
MDXG has a Current ratio of 4.41. This is comparable to the rest of the industry: MDXG outperforms 50.09% of its industry peers.
MDXG has a Quick Ratio of 3.95. This indicates that MDXG is financially healthy and has no problem in meeting its short term obligations.
MDXG's Quick ratio of 3.95 is in line compared to the rest of the industry. MDXG outperforms 48.02% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.41 | ||
| Quick Ratio | 3.95 |
3. Growth
3.1 Past
The earnings per share for MDXG have decreased strongly by -35.71% in the last year.
Looking at the last year, MDXG shows a quite strong growth in Revenue. The Revenue has grown by 14.77% in the last year.
The Revenue has been growing slightly by 3.11% on average over the past years.
EPS 1Y (TTM)-35.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%200%
Revenue 1Y (TTM)14.77%
Revenue growth 3Y10.5%
Revenue growth 5Y3.11%
Sales Q2Q%35.3%
3.2 Future
Based on estimates for the next years, MDXG will show a quite strong growth in Earnings Per Share. The EPS will grow by 16.54% on average per year.
MDXG is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 14.49% yearly.
EPS Next Y47.72%
EPS Next 2Y-7.17%
EPS Next 3Y16.54%
EPS Next 5YN/A
Revenue Next Year18%
Revenue Next 2Y9.77%
Revenue Next 3Y10.75%
Revenue Next 5Y14.49%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 18.76 indicates a rather expensive valuation of MDXG.
MDXG's Price/Earnings ratio is rather cheap when compared to the industry. MDXG is cheaper than 94.54% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 26.49. MDXG is valued slightly cheaper when compared to this.
MDXG is valuated quite expensively with a Price/Forward Earnings ratio of 27.03.
92.84% of the companies in the same industry are more expensive than MDXG, based on the Price/Forward Earnings ratio.
When comparing the Price/Forward Earnings ratio of MDXG to the average of the S&P500 Index (23.69), we can say MDXG is valued inline with the index average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 18.76 | ||
| Fwd PE | 27.03 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, MDXG is valued cheaper than 95.29% of the companies in the same industry.
96.42% of the companies in the same industry are more expensive than MDXG, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 14.97 | ||
| EV/EBITDA | 13.15 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
MDXG has a very decent profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as MDXG's earnings are expected to grow with 16.54% in the coming years.
PEG (NY)0.39
PEG (5Y)N/A
EPS Next 2Y-7.17%
EPS Next 3Y16.54%
5. Dividend
5.1 Amount
MDXG does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:MDXG (12/8/2025, 3:50:02 PM)
6.755
-0.17 (-2.53%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners71.78%
Inst Owner Change-0.7%
Ins Owners1.79%
Ins Owner Change0.17%
Market Cap1.00B
Revenue(TTM)393.44M
Net Income(TTM)40.83M
Analysts81.82
Price Target12.44 (84.16%)
Short Float %3.22%
Short Ratio5.42
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)95.82%
Min EPS beat(2)81.55%
Max EPS beat(2)110.08%
EPS beat(4)3
Avg EPS beat(4)41.67%
Min EPS beat(4)-31.92%
Max EPS beat(4)110.08%
EPS beat(8)7
Avg EPS beat(8)78.91%
EPS beat(12)11
Avg EPS beat(12)70.05%
EPS beat(16)12
Avg EPS beat(16)53.63%
Revenue beat(2)2
Avg Revenue beat(2)12.56%
Min Revenue beat(2)6.68%
Max Revenue beat(2)18.43%
Revenue beat(4)4
Avg Revenue beat(4)6.82%
Min Revenue beat(4)0.32%
Max Revenue beat(4)18.43%
Revenue beat(8)6
Avg Revenue beat(8)3.48%
Revenue beat(12)9
Avg Revenue beat(12)3.71%
Revenue beat(16)12
Avg Revenue beat(16)3.45%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)21.15%
EPS NY rev (1m)-1.18%
EPS NY rev (3m)29.23%
Revenue NQ rev (1m)0.96%
Revenue NQ rev (3m)2.37%
Revenue NY rev (1m)0.11%
Revenue NY rev (3m)5.73%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 18.76 | ||
| Fwd PE | 27.03 | ||
| P/S | 2.54 | ||
| P/FCF | 14.97 | ||
| P/OCF | 14.75 | ||
| P/B | 4.19 | ||
| P/tB | 4.8 | ||
| EV/EBITDA | 13.15 |
EPS(TTM)0.36
EY5.33%
EPS(NY)0.25
Fwd EY3.7%
FCF(TTM)0.45
FCFY6.68%
OCF(TTM)0.46
OCFY6.78%
SpS2.66
BVpS1.61
TBVpS1.41
PEG (NY)0.39
PEG (5Y)N/A
Graham Number3.62
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 12.8% | ||
| ROE | 17.09% | ||
| ROCE | 20.67% | ||
| ROIC | 15.15% | ||
| ROICexc | 33.2% | ||
| ROICexgc | 44.66% | ||
| OM | 13.73% | ||
| PM (TTM) | 10.38% | ||
| GM | 81.99% | ||
| FCFM | 16.98% |
ROA(3y)4.7%
ROA(5y)-7.18%
ROE(3y)1.74%
ROE(5y)-20.73%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5Y-47.46%
ROICexc growth 3YN/A
ROICexc growth 5Y-21.46%
OM growth 3YN/A
OM growth 5Y-1.06%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.19%
GM growth 5Y-0.67%
F-Score6
Asset Turnover1.23
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.07 | ||
| Debt/FCF | 0.27 | ||
| Debt/EBITDA | 0.25 | ||
| Cap/Depr | 6.96% | ||
| Cap/Sales | 0.26% | ||
| Interest Coverage | 36.69 | ||
| Cash Conversion | 98.8% | ||
| Profit Quality | 163.64% | ||
| Current Ratio | 4.41 | ||
| Quick Ratio | 3.95 | ||
| Altman-Z | 9.97 |
F-Score6
WACC8.69%
ROIC/WACC1.74
Cap/Depr(3y)52.31%
Cap/Depr(5y)58.09%
Cap/Sales(3y)0.72%
Cap/Sales(5y)1.07%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-35.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%200%
EPS Next Y47.72%
EPS Next 2Y-7.17%
EPS Next 3Y16.54%
EPS Next 5YN/A
Revenue 1Y (TTM)14.77%
Revenue growth 3Y10.5%
Revenue growth 5Y3.11%
Sales Q2Q%35.3%
Revenue Next Year18%
Revenue Next 2Y9.77%
Revenue Next 3Y10.75%
Revenue Next 5Y14.49%
EBIT growth 1Y-14.78%
EBIT growth 3YN/A
EBIT growth 5Y2.02%
EBIT Next Year63.46%
EBIT Next 3Y22.08%
EBIT Next 5Y22.59%
FCF growth 1Y787.24%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y522.28%
OCF growth 3YN/A
OCF growth 5YN/A
MIMEDX GROUP INC / MDXG FAQ
Can you provide the ChartMill fundamental rating for MIMEDX GROUP INC?
ChartMill assigns a fundamental rating of 6 / 10 to MDXG.
What is the valuation status of MIMEDX GROUP INC (MDXG) stock?
ChartMill assigns a valuation rating of 7 / 10 to MIMEDX GROUP INC (MDXG). This can be considered as Undervalued.
What is the profitability of MDXG stock?
MIMEDX GROUP INC (MDXG) has a profitability rating of 6 / 10.
What is the valuation of MIMEDX GROUP INC based on its PE and PB ratios?
The Price/Earnings (PE) ratio for MIMEDX GROUP INC (MDXG) is 18.76 and the Price/Book (PB) ratio is 4.19.
What is the financial health of MIMEDX GROUP INC (MDXG) stock?
The financial health rating of MIMEDX GROUP INC (MDXG) is 7 / 10.